Pharmaceutical

Atsena’s ATSN-201 gains FDA fast track status for XLRS treatment

Atsena Therapeutics has received fast track designation from the FDA for ATSN-201, aimed at treating X-linked retinoschisis (XLRS).

Mar 13, 2025 - 06:00
Atsena’s ATSN-201 gains FDA fast track status for XLRS treatment
Atsena Therapeutics has received fast track designation from the FDA for ATSN-201, aimed at treating X-linked retinoschisis (XLRS).
Read the original article

Tags:

Previous Article

Exploring Pathways to Cultivate the Amazon’s Bioeconomy

Next Article

Orphelia explores avenues for liquid neuroblastoma med after EU CHMP rejection

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: With Apollo Endosurgery acquisition, Boston Scientific dives into the obesity treatment market

STAT+: With Apollo Endosurgery acquisition, Boston Scie...

Apr 7, 2023

STAT+: Eli Lilly to acquire DICE Therapeutics in $2.4 billion deal

STAT+: Eli Lilly to acquire DICE Therapeutics in $2.4 b...

Jun 20, 2023

STAT+: AstraZeneca buys early-stage gene therapies from Pfizer in boon for struggling field

STAT+: AstraZeneca buys early-stage gene therapies from...

Jul 28, 2023